On March 6, a U.S. Senate committee on Homeland Security and Governmental Affairs will hold a hearing on a bill that would prohibit federal agencies from contracting with China’s BGI, WuXi AppTec, according to Reuters.

A U.S. Committee is seeking sanctions on WuXi AppTec and its affiliate WuXi Biologics, according to a letter dated February 12 and seen by Reuters, stating that the global pharmaceutical company’s links to China’s Communist Party (CCP) and military threatened U.S. national security. Congress introduced legislation that would restrict federally-funded medical providers from allowing China’s BGI Group, WuXi AppTec and other biotech firms from getting genetic information about Americans. Read More
 
Read the lawmakers letter to the Departments of Treasury, Defense, and Commerce
 
Related WuXi news:
In January, WuXi AppTec commissioned two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. The expansion increases the company’s Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, which aims to address increasing global demand for peptide therapeutics. Read More
 
In November 2023, WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), entered into a license agreement with Myricx Bio, a UK biotech company developing a novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), under which Myricx will have exclusive access to an antibody discovered based on WuXi Bio’s integrated technology platforms. Read More

In October 2023 WuXi Biologics launched a new bioprocessing platform WuXiUI, an ultra-intensified, fed-batch solution designed to enhance the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities. Read More
 
In June WuXi Biologics announced it will double capacity at its drug substance facilities in Germany. WuXi has facilities in the United States, China, Singapore, Ireland, and Germany. In 2020 WuXi invested in the construction and adaptation of two facilities in Germany. The Chempark Leverkusen sterile filling and freeze-drying plant will add a second variable filling line. WuXi’s Wuppertal drug substance facility will double total capacity. WuXi’s Leverkusen and Wuppertal facilities will further enhance the company’s commercial and clinical manufacturing capacities in Europe. Read More